The Asia-Pacific genetic testing market is predicted to record a CAGR of 10.49% during the forecast period, 2022-2030, and is set to reach a revenue of $6662.7 million by 2030.

Asia-Pacific is a densely populated region in the world. This enables a large pool of potential patients for genetic testing. Also, the region witnesses a high growth rate globally in terms of newborn babies. In addition, several developed economies of the region, like Taiwan, South Korea, Singapore, Japan, and China, have advanced medical facilities.

To know more about this report, request a free sample copy

The Asia-Pacific genetic testing market growth assessment includes the analysis of South Korea, Indonesia, Australia & New Zealand, Singapore, Japan, China, Taiwan, India, and Rest of Asia-Pacific. China is the second-largest economy globally with innovative technologies. Also, public healthcare has drastically improved in the last 30 years. At present, it is easily accessible and largely public. However, the country faces many emerging public health challenges like respiratory disorders, given the rising air pollution and unbalanced distribution and development of public health care facilities. Additionally, the government initiatives like listing genetic testing as part of the National Development and Reform Commission in the 13^th Five-Year-Plan’s strategy with regard to the biological industry benefit market growth.

Further, several companies in China offer genetic tests directly to consumers. For instance, Genebox provides tests at low costs. Moreover, over 2.2 million Chinese sent test tubes of spit to private companies for their DNA analysis, according to 2019 stats.

In South Korea, genomic medicine is a key domain. Also, precision medicine, genetic testing, direct-to-consumer genetic testing, precision medicine, and genomic research are significantly prioritized in government policies. South Korea has one of the largest biobanks globally. Besides, genetic testing is on the rise for hereditary diseases and cancer diagnoses for personalized treatment. Although a regulatory framework is in place for these tests, quality assurance and health coverage are not in line with the existing demands from clinicians and patients. Furthermore, telecommunications companies and DTC (direct-to-consumer) genetic testing organizations are partnering to help consumers stay informed about their health status. This is done by sending lab results directly to their mobile devices.

The segmentation analysis of the Asia-Pacific genetic testing market includes disease, application, technology, and type. The technology category is further sub-segmented into biochemical testing, cytogenetic testing, and molecular testing. Cytogenetic Testing is an emerging application in terms of revenue share and CAGR.

Cytogenetics is the study of the relationship between genetic diseases and chromosomal aberrations in human beings. It extends beyond the simple description of a genome’s chromosomal status. It further enables the study of fundamental biological questions like the three-dimensional organization of the human genomes, genomic changes in tumorigenesis, and the nature of inherited syndromes. Also, it examines the abnormal and normal chromosomes in relation to disease. Besides, cytogenetic tests are used to acquire prognostic and diagnostic insights into malignancies and solid tumor cancers. This is because these can be a result of altered chromosome numbers.

Some of the key firms in the Asia-Pacific genetic testing market include ELITech Group, Decode Genetics, BGI Group, Eurofins Scientific, etc.

BGI Genomics offers sequencing services and a portfolio of genetic tests for research institutions, public & private partners, and medical institutions. It provides RNA, DNA, and customized sequencing services, clinical exome sequencing services, newborn genetic screening, etc. Also, it offers services in varied research areas like food science & agriculture, metagenomics, drug discovery, biomarker discovery, reproductive health, cancer research, and metagenomics. Moreover, the company’s major operations are in China, with headquarters in Shenzhen, China.

The company offers BGI SENTIS™ Lung Cancer Panel that utilizes genomics to advance precision medicine for cancer. Also, the BGI’s next-generation sequencing assays offer different options, including targeted panels for analyzing genes linked to specific cancers.

Report Synopsis

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.